SARS-CoV-2 vaccines: evolution and escape

Vacunas SARS-CoV-2: evolución y escape

SARS-CoV-2 was declared a pandemic virus a year ago and has caused more than 130 million confirmed cases and 2.8 million deaths worldwide. In late 2020, vaccines based on the SARS-CoV-2 spike protein were the first to be approved in the health emergency. The spike protein interacts with the human ACE2 receptor at the beginning of the infection process, this basic knowledge gave rise to a vaccine whose target of action was the spike to trigger the action of neutralizing antibodies. Vaccines applied in the Western Hemisphere do not follow the traditional route of attenuated or inactive viruses; the new trend is messenger RNA methodologies, some are inserted into viral vectors that present the antigen to the cells of the immune system cells and induce humoral memory. However, vaccines based on recombinant peptides, attenuated and inactive viruses, have been successfully applied in Latin America and Asia, which overcome storage temperature and geopolitical aspects limitations.

1. Worldometer. COVID-19 coronavirus pandemic. [Internet]. Worldometer; 2021. Available from: https://www.worldometers.info/coronavirus/
2. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann AJ, et al. The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020; 5(48):eabc8413. https://doi.org/10.1126/sciimmunol.abc8413
3. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; 383(27):2603–2615. https://doi.org/10.1056/NEJMoa2034577
4. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021; 384(5):403–416. https://doi.org/10.1056/NEJMoa2035389
5. NIH. Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released. USA: National Institutes of Health (NIH); 2021. https://www.nih.gov/news-events/news-releases/janssen-investigational-covid-19-vaccine-interim-analysis-phase-3-clinical-data-released
6. AstraZeneca. COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials [Internet]. Cambridge, UK, AstraZeneca; 2021. https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-confirms-protection-against-severe-disease-hospitalisation-and-death-in-the-primary-analysis-of-phase-iii-trials.html
7. Logunov DY, Dolzhikova I V., Shcheblyakov D V., Tukhvatulin AI, Zubkova O V., Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb 20; 397(10275):671–81. https://doi.org/10.1016/S0140-6736(21)00234-8
8. Sinovac Announces Phase III Results of Its COVID-19 Vaccine-SINOVAC - Supply Vaccines to Eliminate Human Diseases. Available from: http://www.sinovac.com/?optionid=754&auto_id=922
9. Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021; https://doi.org/10.1038/s41591-021-01285-x
10. Callaway E. The coronavirus is mutating - does it matter? Nature. 2020; 585:174-177. https://doi.org/10.1038/d41586-020-02544-6
11. Wu K, Werner AP, Koch M, Choi A, Narayanan E, Stewart-Jones GBE, et al. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. N Engl J Med. 2021. https://doi.org/10.1056/NEJMc2102179
12. Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021. https://doi.org/10.1038/s41586-021-03324-6
13. Garcia-Beltran WF, Lam EC, St. Denis K, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021; 184:1-12. https://doi.org/10.1016/j.cell.2021.03.013
14. van Egeren D, Novokhodko A, Stoddard M, Tran U, Zetter B, Rogers M, et al. Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein. medRxiv. 2020; 11.17.20233726. https://doi.org/10.1101/2020.11.17.20233726
15. Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife. 2020; 9: e61312. https://doi.org/10.7554/eLife.61312